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Abstract
Background: The aim of this work was to investigate in vitro the putative role of EGR-1 in the
growth of glioma cells. EGR-1 expression was examined during the early passages in vitro of 17
primary cell lines grown from 3 grade III and from 14 grade IV malignant astrocytoma explants. The
explanted tumors were genetically characterized at the p53, MDM2 and INK4a/ARF loci, and
fibronectin expression and growth characteristics were examined. A recombinant adenovirus
overexpressing EGR-1 was tested in the primary cell lines.
Results: Low levels of EGR-1 protein were found in all primary cultures examined, with lower
values present in grade IV tumors and in cultures carrying wild-type copies of p53 gene. The levels
of EGR-1 protein were significantly correlated to the amount of intracellular fibronectin, but only
in tumors carrying wild-type copies of the p53 gene (R = 0,78, p = 0.0082). Duplication time, plating
efficiency, colony formation in agarose, and contact inhibition were also altered in the p53 mutated
tumor cultures compared to those carrying wild-type p53. Growth arrest was achieved in both
types of tumor within 1–2 weeks following infection with a recombinant adenovirus overexpressing
EGR-1 but not with the control adenovirus.
Conclusions: Suppression of EGR-1 is a common event in gliomas and in most cases this is
achieved through down-regulation of gene expression. Expression of EGR-1 by recombinant
adenovirus infection almost completely abolishes the growth of tumor cells in vitro, regardless of
the mutational status of the p53 gene.
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Background
EGR-1 encodes a nuclear phosphoprotein that binds to
DNA and regulates transcription through a GC-rich con-
sensus sequence [1-4]. EGR-1 is involved in the regulation
of cell responses to a wide array of stimuli such as
mitogens, growth factors and stress stimuli [5-7]. Recent
studies have shown that EGR-1 expression is altered in
several types of neoplasia, compared to normal tissue
[1,8,9]. Gene deletion or EGR-1  mutations have been
reported in sporadic hematological malignancies [10].
EGR-1 expression has been found to be either decreased
or undetectable in human breast cancer tissue and small
cell lung carcinoma [11,12]. EGR-1 is altered in a different
manner in prostate cancer, where higher levels of EGR-1
expression are found correlated to more advanced stages
of malignancy [13]. Later studies confirmed in two inde-
pendent mouse models that EGR-1 up-regulates tumor
progression [14,15]. From these various studies it is clear
that EGR-1 is involved in regulation of cell proliferation.
In order to test whether Egr-1 is implicated in the patho-
genesis of astrocytic tumors, we recently examined the
expression of EGR-1  RNA and protein in fresh glioma
samples [16]. Compared to human normal brain tissue,
EGR-1 expression was strongly reduced in these tumors,
particularly in cases with normal p53 alleles, suggesting a
role as a tumor suppressor gene. To explore this finding
further, we have extended our study to a new series of 17
primary cell cultures established in our laboratory from
anaplastic astrocytoma and glioblastoma multiforme.
During the first passages in vitro, we not only evaluated
EGR-1 expression but also examined the primary cultures
for proliferative activity and expression of fibronectin, an
important factor in the organization of extracellular
matrix [17]. Fibronectin facilitates cell adhesion and
migration [18] and has been shown to be positively regu-
lated by EGR-1 in the human glioblastoma cell line U251
[19]. In addition, the primary cultures were genotypically
characterized for mutations in the p53, MDM2 and p16/
INK4a/ARF genes [20]. Finally, the effect of EGR-1 on pro-
liferative activity of primary cells carrying wild type or
mutant  p53  genes was investigated by infection with
recombinant adenovirus engineered to overexpress EGR-
1.
Results
EGR-1 expression in glioma cells cultured in vitro
EGR-1 protein expression in the 17 primary cultures was
examined using Western blot analysis. In CRL-8, GSS-98
and MZC-12 an 85 kD band corresponding to full-lenght
EGR-1 was clearly visible (Fig. 1). In the remaining pri-
mary cultures, basal expression of EGR-1 was either
Western blot of EGR-1 expression in glioma-derived primary cell cultures Figure 1
Western blot of EGR-1 expression in glioma-derived primary cell cultures Western blot of EGR-1 expression in 17 
primary cell cultures derived from tumors resected from patients affected by grade III astrocytoma or glioblastoma multiforme 
(grade IV). Controls include normal adult astrocytes, the established glioblastoma cell lines U251, T98G and A172, and the 
U251 cell line after stimulation with PMA. EGR-1 is clearly detected in normal astrocytes, in PMA stimulated U251 cells, and at 
lower levels in a few tumor primary cultures and in all three established cell lines. EGR-1 was detected by enhanced chemilumi-
nescence after film exposure of 10 min.Cancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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undetectable or faintly present. EGR-1 protein was
detected in normal astrocytes and in the U251 cell line
stimulated with PMA [19], serving as positive control; The
basal expression of EGR-1 in the U251 and two additional
glioblastoma cell lines (T98G, and A172) was also exam-
ined and found moderately present in all the three estab-
lished glioblastoma cell lines. Densitometric
measurements indicated that EGR-1 protein levels in the
three positive tumor cultures were at least 20-fold lower
than the level found in the unstimulated normal astro-
cytes, supporting the hypothesis that EGR-1 expression is
downregulated in malignant tumors.
EGR-1 protein expression in tumor primary cultures was
also examined by immunocytochemistry. Weakly positive
cells were present in all primary cultures. As shown in Fig.
2, the fraction of immunolabeled cells ranged from 5 to
83%, with a mean ± s.e value of 39.8 ± 4.9. The three pri-
mary cultures with the highest frequency of EGR-1-posi-
tive cells by immunocytochemistry (CRL-8, 83%; GSS-98,
62%; and MZC-12, 55%) were also the three cultures that
showed clear expression of EGR-1 protein by Western blot
analysis.
The finding that all tumor primary cultures showed EGR-
1 protein expression by immunocytochemistry led us to
reexamine the Western blot analysis by increasing the
exposure time from approximately 10 minutes to over 30
minutes. With increased exposure, EGR-1 protein was
detected as a weak signal in all tumor primary cultures
previously found negative. The EGR-1-specific bands in
the primary cultures were quantified following densito-
metric scanning and normalization (see Table 1, in Addi-
tional file 1). Western blot data and
immunocytochemistry data correlate significantly (R =
0.703, p = 0.0084). In addition, Northern blot analysis of
EGR-1 expression confirmed the results seen with Western
blot analysis (data not shown). The results of these analy-
ses suggest that EGR-1 gene expression is strongly down-
Quantitative evaluation of EGR-1 expression Figure 2
Quantitative evaluation of EGR-1 expression Quantita-
tive evaluation of EGR-1 expression in 17 glioma primary cell 
lines. Data are given as percent of labelled cells measured by 
immunocytochemistry.
Stimulation of EGR-1 expression by the endogenous gene Figure 3
Stimulation of EGR-1 expression by the endogenous 
gene Western blot of EGR-1 in CRL-8 and FCN-9, estab-
lished from glioblastoma multiforme and astrocytoma grade 
III, respectively. EGR-1 protein synthesis was up-regulated by 
the endogenous gene in the two primary cell cultures after 
being exposed to different types of external stimuli, suggest-
ing that EGR-1 expression was regulated at the level of tran-
scription. The characteristics of the two cell lines are 
described in Table 1 (see Additional file 1). Q, cells made qui-
escent in serum depleted medium for 24–48 hrs; N, cells 
growing at log phase in medium with 10% serum (control 
cells); 20% FCS, quiescent cells stimulated with serum 
enriched medium for 24–48 hrs; Q + UV, quiescent cells 
stimulated by UV irradiation (40 J/m2); N + UV, exponentially 
growing cells stimulated by UV irradiation. PMA, quiescent 
cells stimulated by PMA (100 ng/ml). A typical experiment is 
shown.Cancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
Page 4 of 12
(page number not for citation purposes)
regulated in primary cultures derived from malignant
glioma.
EGR-1 expression in glioma can be up-regulated in vitro by 
PMA and UV stimulation
The reduced levels of EGR-1 in glioma primary cultures
could be due to gene inactivation or mutation. To deter-
mine whether EGR-1 expression could be up-regulated in
these cells in response to external stimuli, we treated qui-
escent tumor cells with PMA (100 ng/ml), UV irradiation
(40 J/m2) for 2 hours, or serum. These stimuli are known
to induce both mRNA and protein synthesis of EGR-1
[4,21]. EGR-1 protein expression was differentially
induced by all these stimuli. The protein migrated with an
apparent size of 85 kDa, very similar to full-length normal
EGR-1. Our data suggest that EGR-1 gene transcription
and transcription processing remain intact after the onco-
genic process, but that steady-state expression is selec-
tively reduced. Results of a typical experiment performed
with primary cultures FCN-9 and CRL-8 are shown in Fig.
3.
Mutational profile and differentiation markers
The 17 primary cell lines were analyzed for mutations in
exons 5–9 of the p53 gene, for MDM2 gene amplification,
and for loss of heterozygosity at the INK4A-ARF locus
(Table 1, see Additional file 1). p53 gene mutations were
present in three cases. CRL-8 and MZC-12 had
homozygous mutations leading to amino acid substitu-
tions at codon 216 of exon 6 (Val -> Met) and at codon
248 of exon 7 (Arg -> Glu), respectively. In the third case,
FCN-9, a mutation occurred at the AG donor (AG to AA)
located at the 3' splice site of exon 6. In order to determine
whether these mutations affected protein stabilization, we
performed immunofluorescence staining for the p53 pro-
tein. In FCN-9 cells, accumulation of p53 protein was seen
in only a small fraction (10%) of cells. By contrast, p53-
positive cells were detected at a >70% frequency in CRL-8
and MZC-12 cells (Table 1, see Additional file 1). We
concluded that EGR-1 was expressed at significantly (p =
0.026) higher levels in the p53-mutated primary cultures
(370.6 integrated O.D. ± 167.2) compared to primary cul-
tures with wild-type p53 (133.3 integrated O.D. ± 18.9).
Southern analysis indicated that none of the primary cell
lines carried amplified copies of MDM2 gene (data not
shown). In all cell lines but one, indirect immunofluores-
cence detected low levels of MDM2 protein, compatible
with the presence of normal copy number of the MDM2
gene. The exception was the primary cell line BMR-76,
which was negative for MDM2 protein (Table 1, see Addi-
tional file 1). Homozygous deletions at the INK4A-ARF
locus were found in FLS-10 and GSS-98.
The differentiation status of tumor cells was assessed by
examining glial fibrillary acidic protein (GFAP) and
vimentin expression, which were demonstrated in 6 and
11 tumor primary cultures, respectively (Table 1, see Addi-
tional file 1). Neither MDM2 levels nor the presence of
GFAP or vimentin correlated with EGR-1 expression.
Glioblastoma (grade IV) tumors carrying wild-type p53 
have less EGR-1 than do anaplastic astrocytoma (grade III) 
tumors
Primary cultures from glioblastoma multiforme carrying
normal copies of p53 gene had both a lower percentage of
EGR-1 positive cells (32.2% ± 4.8) and lower levels of
EGR-1 protein (116.2 integrated O.D. ± 16.9) than did
grade III astrocytoma-derived cultures (57.5% ± 4.5 and
335.5 integrated O.D. ± 84.5, respectively). The difference
between the two tumor types with respect to EGR-1 pro-
tein levels was highly significant (p = 0.0009).
Fibronectin expression and EGR-1 expression are strongly 
correlated in tumors carrying wild-type copies of p53 gene
Fibronectin has an important role in organizing the extra-
cellular matrix and facilitates cell adhesion, migration and
tumor metastasis [18], and recent work has shown that
EGR-1 can positively regulate expression of the
fibronectin gene in vitro [19]. Since the low levels of EGR-
1 protein found in our primary cultures may suggest that
EGR-1 is functionally inactivated, we examined
fibronectin expression in these cells to determine whether
fibronectin protein levels were similarly decreased. To rule
out the possibility that fibronectin expression might arise
from contamination of the primary cultures by mesen-
chyme cells or other tumor supportive cells, we first tested
for cell contamination by performing extensive immuno-
cytochemical reactions with S-100 protein and neurofila-
ment proteins, cytokeratins, basic myelin protein and
neuron-specific-enolase. Results showed that our primary
cultures consisted almost entirely of tumor cells (data not
shown) and supported the conclusion that cell contami-
nation was negligible during the short time the cells were
under observation
We examined the intracellular accumulation of fibronec-
tin by Western blot analysis in 11 randomly selected cul-
tures from the panel of the 17 tumor primary cultures and
detected fibronectin in all tumors tested. The normalized
values of integrated O.D.3 varied from less than 200 to
more than 1600 and increased linearly with the amount
of EGR-1 in the tumor primary cultures homozygous for
wild type p53 (R = 0.78, p = 0.0082). In the primary cell
lines with mutated p53 genes, only low levels of fibronec-
tin were found, despite a wide range in EGR-1 levels.Cancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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Growth assays
To determine whether primary cell cultures with different
levels of EGR-1 have different growth properties in vitro,
we tested the tumor cells cultured between the second and
third passage for duplication time, plating efficiency, abil-
ity to grow as colonies in soft agarose, and sensitivity to
contact inhibition (Table 1, see Additional file 1). The
duplication time ranged from 36 hours to over 10 days
(mean ± s.e. = 82.3 hours ± 13.8; median duplication time
= 69 hrs). Plating efficiency, measured as the percentage of
cells that proliferate as surface-attached colonies when
plated at low density, ranged from 11% to 80% (mean ±
s.e. = 29.2% ± 4.8; median plating efficiency = 30%)
among primary cultures that formed colonies. Two of the
tumor primary cultures tested, CDR-97 and GSS-98, did
not form colonies. Lowering the serum concentration
from 10% to 2.5% reduced or abolished plating effi-
ciency: only six cultures, including the three with p53
mutations, proliferated under this condition (mean ± s.e.
= 2.1% ± 1.9). Eleven of 17 tumor primary cultures
formed colonies in soft agarose, the percentage of cells
growing as colonies ranging from 0.01% to 6%. Finally,
growth inhibition by cell-to-cell contact was evaluated by
culturing the 17 tumor primary cultures at high cell den-
sity. Only cell cultures with p53 mutations continued to
grow after cell confluence, giving rise to typical transfor-
mation-associated growth foci.
In summary, compared to the 14 primary cultures
homozygous for wild-type p53, the three tumor primary
cultures with p53 mutations not only contain signifi-
cantly higher levels of EGR-1 protein (see previous section
"Mutational profile and differentiation markers"), but
also have shorter duplication times (compared to the
median duplication time of 69 hrs), higher mean plating
efficiency at low serum concentration (9.33% vs. 0.61%,
p = 0.0017) and higher mean agarose cloning ability
(4.03% vs. 0.65%, p = 0.005). Within the group of cul-
tures homozygous for wild-type p53, none of the growth
parameters correlated with EGR-1 expression, and no dif-
ferences in the levels of EGR-1 were found between any of
the cell lines homozygous for wild-type p53, regardless of
growth characteristics.
Functional EGR-1 introduced via recombinant Adenovirus 
infection drastically reduces cell growth in vitro
In view of the above results, we finally investigated the
effect of EGR-1 on cell growth after reconstitution of func-
tional EGR-1 levels via recombinant Adenovirus infec-
tion. A replication deficient Adenovirus vector harbouring
EGR-1 cDNA (AdGFP-EGR-1) was used to deliver EGR-1
into five different primary cell cultures (MZC-12, LTN-12,
CRL-8, FCN-9 and BRT-5, this last not included in Table
1, see Additional file 1), and into the established glioma
cell lines U251 and U87MG for comparison. The AdGFP
adenovirus vector carrying the GFP gene alone was used as
a control.
Within 24 hours after viral infection EGR-1 could be
detected in cells infected with the adenovirus constructs
carrying the EGR-1 transgene, but not in cells infected
with the control virus. EGR-1 reached maximal expression
after approximately two days and remained detectable for
as long as 12 days, which was the maximum time
investigated in time-course protein expression experi-
ments. Fig. 5 shows EGR-1 expression in three representa-
tive cell lines following infection with the control and
EGR-1-containing constructs. Cell growth experiments
from repeated infections were highly reproducible, yield-
ing comparable results among the different cell lines.
Growth arrest of the AdGFP-EGR-1 infected cells was
clearly manifest from day 5 post-infection. A four- to six-
fold reduction of proliferation was usually achieved
between days 7 to 12 by the AdGFP-EGR-1 infected cells
compared to cells infected with control vector. Interest-
ingly, cell growth inhibition by EGR-1 occurred in both
primary cultures (regardless of p53 status) and established
cell lines. Differences in the growth magnitude between
CRL-8 and LTN-12 can be largely explained by the much
longer duplication time of LTN-12 (see Table 1, in Addi-
tional file 1). U251 cells were examined only up to seven
days post-infection, as control cells reached full conflu-
ence thereafter.
Expression of fibronectin in primary cell lines carrying wild- type or mutant p53 Figure 4
Expression of fibronectin in primary cell lines carry-
ing wild-type or mutant p53 Both fibronectin and EGR-1 
are expressed as units of integrated O.D. measured by densi-
tometric analysis of Western blot. Fibronectin protein 
increases linearly with the amount of EGR-1 in tumors 
homozygous for wild-type p53 (wt p53) (R = 0.78, p = 
0.0082). Tumors with mutated copies of p53 (mut p53) have 
only low levels of fibronectin.Cancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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Exogenous EGR-1 induces growth arrest in glioma primary cell lines and in U251 cells Figure 5
Exogenous EGR-1 induces growth arrest in glioma primary cell lines and in U251 cells. Left side: growth curves of 
CRL-8 (upper), LTN-12 (middle), and U251 (lower) following infection at day 0 with either a recombinant adenovirus express-
ing an EGR-1 transgene (AdGFP-EGR-1), or control vector carrying the GFP gene insert (AdGFP). Cell growth is given by 
absorbance units of cell lysates pre-treated with sulphorhodamine B. Cell viability exceeded 90% in control vector-infected cell 
lines. Duplication times are 23 hrs for U251, 66 hrs for CRL-8, and 100 hrs for LTN-12, allowing for differences between cell 
lines for cell growth (see LTN-12 versus CRL-8 and U251) or for the length of the reported observation period (see U251 ver-
sus CRL-8 and LTN-12). Right side: immunoblot analysis of EGR-1 and β-actin protein extracted from CRL-8 (upper), LTN-12 
(middle), and U251 (lower) at days 0, 5 and 7 following infection at day 0 with either AdGFP-EGR-1 or control vector.Cancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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For more than 70% of the growth-arrested cells expressing
exogenous EGR-1, growth inhibition was eventually fol-
lowed by drastic changes in morphology. These changes
consisted of reduction in cell volume, cell rounding, and
eventual detachment of the cells from the bottom of the
culture dish (Fig. 6). Similar changes were observed in
fewer than 10% of cells infected with control virus.
Discussion
EGR-1 is an important factor in regulating cell growth. In
tumor cells two alternative patterns of EGR-1 expression
have been recognized. In prostate cancer, EGR-1 levels are
elevated in tumor cells [13]. By contrast, EGR-1 expression
is often low or absent in breast and lung tumors [11,12],
suggesting that EGR-1 may have tumor suppressive func-
tions in some cancer types.
In the present study we investigated EGR-1 expression in
a group of 17 newly established primary cultures of ana-
plastic astrocytoma and glioblastoma multiforme and
showed that EGR-1 is down-regulated in these tumors
compared to normal astrocytes. Basal levels of EGR-1
expression in normal astrocytes have been reported also
by other investigators [22-24]. Our data thus support the
hypothesis that EGR-1 may have tumor suppressive func-
tions, as for breast and lung tissues. Among the tumor
cultures with wild-type p53, those derived from glioblast-
oma multiforme had significantly (p = 0.0009) lower
Morphology of cells treated with recombinant Adenovirus Figure 6
Morphology of cells treated with recombinant Adenovirus Morphology of LTN-12 at seven days after infection with 
either a recombinant adenovirus expressing an EGR-1 transgene (B, D), or control vector carrying the GFP gene insert (A, C). 
Upper panel: phase contrast magnification. Lower panel: cell nuclei were stained with Hoechst dye.Cancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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EGR-1 expression than did tumor cultures derived from
grade III astrocytoma. In addition, cultures with wild-type
p53 had significantly (p = 0.026) lower EGR-1 expression
than cultures with mutant p53. All together, these findings
are entirely consistent with our previous observations
concerning EGR-1 RNA expression in fresh biopsies from
glioma [16], and support the hypothesis that primary cul-
tures provide a reliable model for examining the role of
the EGR-1 gene in the maintenance and progression of the
glioma phenotype. In fact, permanent cell lines may offer
a less realistic model of the tumor of origin. Their inherent
instability at the genomic level and the elevated number
of duplications they have gone through during their
lifespan in vitro result in accumulation of a series of
genetic alterations, leading to the expansion of highly
transformed, clonally selected subpopulations [25,26].
This is further exemplified by the finding that the p16 gene
is deleted in most established cell lines, irrespective of the
p53 gene status, whereas in our tumor primary cultures
mutations in the p53 and p16/INK4a/ARF genes are car-
ried in a mutually exclusive pattern, as in fresh biopsies
[16,27,28].
Another issue we investigated was whether EGR-1 pre-
serves its role as a regulator of cell proliferation in the in
vitro explanted tumors, where it is expressed in lower lev-
els compared to normal tissue. We investigated several cell
growth parameters including duplication time, contact
inhibition, plating efficiency and agarose clonability, and
we attempted to find a correlation between these parame-
ters and either the levels of EGR-1 protein and/or the
presence of genetic mutations. We found a correlation
between aberrant cell growth and p53 mutations. Com-
pared to the tumor cultures homozygous for wild-type
p53, the primary cultures with mutated copies of the p53
gene show loss of contact inhibition, have lower duplica-
tion times, have significantly (p = 0.0017) higher plating
activity at low serum concentration, and significantly (p =
0.005) higher ability to form colonies in soft agarose.
Interestingly, these cells also expressed higher levels of
EGR-1 thus pointing to a link between the occurrence of
p53 mutations and greater EGR-1 expression. Primary cul-
tures carrying wild type p53 have lower levels of EGR-1,
and there is no correlation between EGR-1 expression and
growth properties in these cases. On the basis of this evi-
dence we hypothesize that inactivation of either p53
(through gene mutations) or EGR-1 (via down-regulated
expression) is an important step leading to unrestricted
proliferation of tumor cells. Glial tumor cells carrying
mutant copies of p53 are more aggressive, irrespective of
EGR-1 expression, than cells carrying wild type copies of
p53, in which EGR-1 expression is almost undetectable.
We examined the intracellular expression of fibronectin in
the tumor primary cultures and observed two distinct
patterns of fibronectin expression. In tumor primary cul-
tures carrying wild type copies of p53, fibronectin accumu-
lated in amounts proportional to the levels of EGR-1
protein. In tumor primary cultures with p53 mutations,
however, only small amounts of fibronectin were seen,
with no correspondence to EGR-1 levels. Our results pro-
vide further data in support for the experimental observa-
tion that EGR-1 directly transactivates the fibronectin
gene in the U251 cell line [19] and suggest that EGR-1
may have retained this control only in tumors carrying
wild type copies of p53. Whether regulation of fibronectin
is part of a wider control EGR-1 exerts on the glioma phe-
notype, other than growth inhibition, remains to be
investigated. Fibronectin expression is also inversely cor-
related with the degree of histological malignancy, cell
transformation and dedifferentiation [29,30]. Together,
these observations support our findings of a direct
involvement of EGR-1 in the negative regulation and con-
trol of glial malignancies.
We used a recombinant adenovirus to introduce a func-
tional EGR-1 cDNA into glioma primary cell lines with
either normal or mutated copies of p53 gene. The exoge-
nous expression of EGR-1 resulted in growth arrest and
eventual cell death, even in the presence of mutated cop-
ies of p53. Mutant p53 may hinder the suppressor activity
of EGR-1, perhaps by direct protein-protein interaction.
Liu et al [31] have recently shown that EGR-1 and P53
form molecular complexes in vitro. Although these find-
ings have not been further confirmed, they allow specula-
tion that binding of mutant p53 protein might inhibit
functional EGR-1 protein. This scenario would be consist-
ent with our results showing that differences in fibronec-
tin expression are supported by differences in EGR-1
levels only in tumor cultures carrying wild-type p53, but
at variance with our finding that the exogenously added
EGR-1 arrested the growth of primary cultures irrespective
of p53 status. One explanation may be that the high levels
of EGR-1 protein expressed by the transgene saturates the
inhibitory effects of the dominant mutant p53 gene.
In summary, the simplest interpretation of our observa-
tions is to attribute the failure of EGR-1 protein to inhibit
glioma cell proliferation to downregulation of the EGR-1
gene in the tumor cells. Our data bear strong implications
for EGR-1 as a future candidate in gene therapy of tumors.
Methods
Glioma primary cell cultures and cell lines
Primary cell lines were established from 17 astrocytic neo-
plasms obtained from patients undergoing surgery.
Tumors were classified according to the WHO classifica-
tion system as anaplastic astrocytoma (W.H.O. grade III; 3
tumors) and glioblastoma multiforme (W.H.O. grade IV;
14 tumors) [32]. Written informed consent for researchCancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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use of tumor tissue was obtained from each patient prior
to surgery, according to a protocol approved by the insti-
tutional ethics committee.
Tumor specimens were immediately transported to the
laboratory, finely minced to single cell suspension and
cultured in complete medium (Dulbecco's modified Eagle
medium containing 10% fetal calf serum and 2%
glutamine) into 100 cm2 tissue culture plastic dishes (Fal-
con, Becton Dickinson) until passage 2. Cells were then
collected and aliquots were cryopreserved in liquid nitro-
gen. One aliquot of cells was kept in culture and grown to
confluence. Cells used in these experiments were subcul-
tured for no more than three additional passages. If addi-
tional cells were needed, another aliquot was thawed and
cultured. The human glioblastoma cell lines U251, T98G
and A172 (obtained from the American Type Culture Col-
lection, Rockville, MD) were cultured in complete
medium.
RNA extraction and Northern Analysis
Total RNA was extracted from tumor primary cultures
using the Ultraspec(tm) RNA isolation system (Biotecx
Laboratories, Houston, TX, USA). Northern blots were
performed as described [16], with 20 µg of RNA used in
each lane. A 1.6 Kb Bgl II fragment from pCMV-EGR-1
plasmid was the probe for EGR-1 [9].
Western Blot Analysis
EGR-1 is easely detected in whole cell extracts [11]. Pro-
teins from cultured cells were extracted in TBS 1% Triton
lysis buffer (150 mM NaCl; 50 mM Tris-HCl pH 8; 5 mM
EDTA; 1 mM NaF; 1 mM Na4P2O7; 1.5 mM KH2PO4; 0.4
mM Na3PO4) and incubated on ice for 20 min. After sam-
ples were centrifuged briefly at 12,000 g, protein concen-
tration was determined using the BioRad protein assay
reagent (Bio-Rad, Hercules, CA, USA). One hundred
micrograms of protein were added to an equal volume of
2 × sample buffer (125 mM Tris-HCl pH 6.8; 4% SDS;
10% glycerol; 0.006% bromophenol blue; 2% mercap-
toethanol), boiled for 5 min, separated on 7% SDS-PAGE
and electrophoretically transferred onto nitrocellulose
membranes (Schleicher & Schuell, Germany). After trans-
fer, Ponceau staining was used for confirmation of equal
protein loading and for signal normalization.
The membranes were incubated for 1 h at room tempera-
ture with PBS containing 5% non-fat dry milk (Bio-Rad)
and then incubated overnight at 4°C in PBS containing
2.5% non-fat dry milk and 1 µg/ml of specific antibody,
either rabbit polyclonal anti-EGR-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) or monoclonal anti-human
fibronectin (Sigma, St. Louis, MO, USA). The membranes
were washed twice with PBS and re-incubated for 1 h with
anti-rabbit or anti-mouse secondary antibody conjugated
with horseradish peroxidase (Amersham Italia Srl,
Milano, Italy). Signals were detected using enhanced
chemiluminescence (ECL detection system; Amersham
Italia Srl) according to the manufacturer's instructions.
Immunofluorescence and immunocytochemistry
Antibodies used were as follows: the rabbit polyclonal
anti-EGR-1 also used for Western blots (Santa Cruz Bio-
technology), a mouse monoclonal antibody against GFAP
(Sigma), and mouse monoclonal antibodies against p53,
MDM2 and vimentin (Pharmingen Corporation, San
Diego, CA, USA). For immunofluorescence, primary cells
were fixed in 4% fresh paraformaldehyde for 5 min and
then permeabilized with 0.1% Triton-X100/PBS for 5
min. Anti-rabbit or anti-mouse fluorescein-conjugated
secondary antibody (Sigma) was used at a 1:100 dilution.
Immunocytochemistry was performed using avidin-
biotin-peroxidase (ABC Universal kit, Vector Laboratories,
Burlingame, CA, USA) following the manufacturer's pro-
tocol. Endogenous peroxidase was inhibited by incuba-
tion with freshly prepared 3% hydrogen peroxide for 10
min. Slides were then washed in PBS buffer (0.05 M Tris-
HCl pH 6.7, 0.3 M NaCl, and 0.1% Tween 20), and cells
fixed on the slide were treated with 1.5% blocking serum
(Santa Cruz Biotechnology) in PBS for 20 min to reduce
non-specific antibody binding. Cells were incubated over-
night with primary antibody, washed, and further
processed with the ABC Universal Quick kit (Vector
Laboratories,), according to the manufacturer's instruc-
tions. Peroxidase activity was visualized after 6 min incu-
bation with freshly prepared 3,3'-diaminobenzidine
substrate solution. Cells were rinsed in water, counter-
stained with hematoxylin, dehydrated, and mounted. All
the values for immunochemistry are expressed as percent-
age of positive cells stained.
Fluorescence at the single cell level was captured with a
Spot II CCD camera (Diagnostic Instruments Inc, Sterling
Heights, MI, USA) mounted on a Axiophot II microscope
(Zeiss, Germany) equipped for epifluorescence. The fluo-
rescence intensity was determined by semi-quantitative
densitometric analysis using the NIH Image software (see
below).
Densitometric Analysis
Densitometric analysis of Western blots was performed
on a Macintosh G3/233 computer using the public
domain NIH Image software (developed at the U.S.
National Institutes of Health and available on the Internet
at http://rsb.info.nih.gov/nih-image). Total protein con-
tent of each sample after loading was estimated by averag-
ing the intensity values of the single major bands of
protein detected by Ponceau staining of filter blots. TheCancer Cell International 2004, 4 http://www.cancerci.com/content/4/1/1
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EGR-1 and fibronectin chemiluminescence signals were
normalized with respect to actin content of each sample.
Evaluation of MDM2 content in cells stained by immun-
ofluorescence was performed by semi-quantitative densit-
ometric analysis of the intensity of fluorescence at the
single cell level.
DNA Sequencing of p53 Exons 5–9
For analysis of p53  mutations, previously described
primer sets were used for PCR amplification from high
molecular weight DNA of three DNA fragments corre-
sponding to p53 exons 5 and 6, exon 7, and exons 8 and
9, respectively [33]. Direct sequencing of the specific DNA
fragments was performed using a Big Dye terminator DNA
sequencing kit with the ABI PRISM 377 DNA Sequencer
(PE Applied Biosystems Inc., Foster City, CA, USA),
according to the manufacturer's instructions. Results were
analyzed using the ABI sequencing analysis software.
Analysis of allele dosage for MDM2 and loss of 
heterozygosity for p16/ARF
Southern blotting was used for monitoring MDM2 gene
amplification and loss of heterozygosity at the p16INK4a/
ARF locus, using procedures and probes as previously
reported [16].
Growth assays
Duplication time
cells were seeded at 2 × 103 per well in 96-well plates in
complete medium. Every two days the growth was meas-
ured by crystal violet assay. The cells were stained and the
dye was released by citrate buffer for quantification in an
ELISA reader. Since cells vary in size between different pri-
mary cultures, the relationship between cell number and
absorbance was first calculated for each primary culture.
The duplication time was calculated by measuring the dis-
tance on the time axis during the log phase of cell growth.
Plating efficiency
clonogenicity on plastic substrate was tested by seeding
200 cells per well in 6-well plates. Cells were cultured in
complete medium containing either 10% or 2.5% FCS
and fed every two days. After three weeks, the cells were
washed in PBS, fixed in 70% ethanol and stained with
crystal violet for colony counting.
Soft agar colony growth
2 × 103 cells were seeded in 0.35% NuSieve low melting
agarose (FMC Bioproducts, Rockland, ME, USA) into 35-
mm dishes previously lined with 0.7% agarose medium.
After three weeks the colonies were counted under the
inverted microscope.
Construction of recombinant Adenoviruses
Recombinant adenoviruses were generated following the
method described by He et al. [34]. Briefly, a 1.7-kb Ava II
fragment containing the EGR-1  coding sequence was
subcloned from plasmid pRSVEgr-1-2.1 [35] into the mul-
tiple cloning site of the shuttle vector pAdCMV-GFP con-
taining the coding sequence of green fluorescent protein
(GFP) under the control of CMV promoter. The resulting
plasmid was linearized by digestion with PmeI and co-
transfected with the adenoviral backbone plasmid
pAdEasy-1 (Stratagene, San Diego, CA, USA) into E. coli
BJ5183 cells, generating recombinant plasmid pAdCMV-
GFP-EGR-1. The recombinant adenovirus AdGFP-EGR-1
was obtained by transfecting pAdCMV-GFP-EGR-1 into
adenovirus packaging 293 cells. A recombinant AdGFP
construct without an insert was also generated and used as
a control. The recombinant adenoviruses were collected at
seven days post-infection. All adenovirus constructs were
amplified and titrated in 293 cells.
For transgene expression the U251 and glioma primary
cultures were grown to about 70% cell confluence and
infected by adding the virus with serum-free medium. The
virus concentration used for infection was chosen by
determining the highest dilution at which optimal
transgene expression could be obtained with low cell tox-
icity. At this concentration between 70% to 90% of cells
were infected each time.
For the cell proliferation assay, cells were seeded at 24
hours after infection onto microtiter plate wells at the
density of 1500 cells/well. After cell fixation in 50% TCA,
the sulforhodamine B assay was performed to quantitate
the viable cells [36].
Statistical analysis
The mean values of measurements of either protein
expression made by densitometry or growth parameters
were compared by two side Student's t test or non para-
metric Mann-Whitney U test. Statistical analysis and cal-
culation of the regression coefficients were performed
using StatView software (SAS Institute Inc., Cary, NC,
USA).
List of abbreviations
The abbreviations used are: PMA, phorbol 12-myristate
13-acetate; GFP, green fluorescent protein; GFAP, glial
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